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Primary neuroblastoma tumors rarely display mutations in the TP53 gene (2%) 
suggesting that the TP53 pathway is impaired at different levels. These include 
amplification of MDM2, cytoplasmatic sequestration of TP53, unfavorable 
conformations for integration in transcriptional complexes, resulting in reduced 
transcriptional activity of the protein. Long non-coding RNAs form a novel class of 
RNA molecules and have not yet been explored as putative components of the TP53 
pathway in neuroblastoma. Recent work demonstrated that TP53 induces long non-
coding RNA (lncRNA) expression in various cancer types to modulate different 
aspects of the TP53 tumor suppressor function. Through further dissection of the 
TP53 pathway in neuroblastoma, we aim to identify lncRNAs acting as downstream 
effectors of TP53.  
Two neuroblastoma model systems were treated with nutlin-3a for 24h to induce 
TP53 activity and lncRNA expression was measured using a custom microarray 
platform detecting 17000 lncRNA genes. Of these, 46 were differentially expressed 
upon TP53 activation.  Expression analysis of a nutlin-3a time-course experiment at 
4, 8 and 24 hours, together with integration of CAGE seq data and in house 
generated H3K27 acetylation data, led to the identification of a core set of lncRNAs 
that were highly responsive to TP53 activity. Several of these lncRNAs demonstrated 
TP53 binding events in their promoter region. Interestingly, some of these lncRNAs 
were associated with survival, age, stage and MYCN status in a cohort of 80 
neuroblastoma patient samples.  Perturbation of these lncRNAs using antisense 
oligonucleotides is currently ongoing and could provide novel insights in their role in 
the TP53 pathway in neuroblastoma.  
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